13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001622627
Total reported value
$269.2M
$269.2M
34 檔
30.9%
The Q1 2025 SEC filing reveals that Rosalind Advisors, Inc. held a total portfolio value of $269.2M, covering 34 public equity positions.
During Q1 2025, Rosalind Advisors, Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including DCTH, VSTM, XERS) accounted for 30.9% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems Inc | Stock-Other | 14.10% | +3.13% | +9.43% | |
| 2 | VSTM | Verastem Inc | Stock-Other | 7.75% | +1.11% | +193.84% | |
| 3 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 6.66% | +1.03% | -19.61% | |
| 4 | MYO | Myomo Inc | Stock-Other | 6.32% | +0.37% | -9.85% | |
| 5 | IDYA | Ideaya Biosciences Inc | Stock-Other | 5.58% | — | — | |
| 6 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 5.28% | +5.54% | +41.51% | |
| 7 | URGN | UroGen Pharma Ltd. | Stock-Other | 5.11% | — | +9.20% | |
| 8 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.34% | — | +7.97% | |
| 9 | ABEO | Abeona Therapeutics Inc | Stock-Other | 4.18% | — | +0.02% | |
| 10 | REPL | Replimune Group Inc | Stock-Other | 4.03% | — | +226.92% | |
| 11 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.90% | -1.97% | EXIT | |
| 12 | ✓ | Mediwound LTD | Stock-Other | 3.83% | -0.76% | -19.29% | |
| 13 | SVRA | Savara Inc | Stock-Other | 3.58% | +0.24% | — | |
| 14 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 3.09% | — | -33.33% | |
| 15 | NSPR | Inspiremd Inc | Stock-Other | 2.98% | -1.54% | -8.85% | |
| 16 | HELP | Cybin Inc | Stock-Other | 2.50% | +1.85% | — | |
| 17 | NUVB | Nuvation Bio Inc | Stock-Other | 2.10% | — | — | |
| 18 | PROF | Profound Medical CORP | Stock-Other | 1.96% | -0.11% | — | |
| 19 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.87% | — | -42.32% | |
| 20 | PHVS | Pharvaris N.V. | Stock-Other | 1.71% | — | — | |
| 21 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.71% | — | — | |
| 22 | ✓ | Polypid LTD | Stock-Other | 1.34% | -0.32% | — | |
| 23 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.19% | — | — | |
| 24 | CMPS | Compass Pathways PLC | Stock-Other | 1.15% | — | +16.34% | |
| 25 | OPTNUSD | Optinose Inc | Stock-Other | 1.14% | — | -70.79% | |
| 26 | COGT | Cogent Biosciences Inc | Stock-Other | 0.72% | — | — | |
| 27 | TLPH | Talphera Inc | Stock-Other | 0.48% | +0.97% | +226.41% | |
| 28 | KPRX | Kiora Pharmaceuticals Inc | Stock-Other | 0.37% | — | -0.20% | |
| 29 | KURA | Kura Oncology Inc | Stock-Other | 0.32% | +0.08% | — | |
| 30 | ACOG | Alpha Cognition Inc | Stock-Other | 0.26% | — | -58.52% | |
| 31 | BFRI | Biofrontera Inc | Stock-Other | 0.25% | +0.07% | -20.63% | |
| 32 | ✓ | Invesco QQQ Tr Put Option 06/2 | Stock-Other | 0.18% | -0.42% | EXIT | |
| 33 | ✓ | Lexicon Pharmaceuticals Inc | Stock-Other | 0.01% | — | — | |
| 34 | ✓ | Candel Therapeutics Inc | Stock-Other | — | — | -93.98% |
According to official SEC Form 13F filings, Rosalind Advisors, Inc. reported a total U.S. public equity portfolio value of $269.2M across 34 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2025, Rosalind Advisors, Inc.'s top holdings by market value included DCTH (14.1%)、VSTM (7.8%)、XERS (6.7%). The largest single position, DCTH, represented 14.1% of total portfolio value.
In Q1 2025, Rosalind Advisors, Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.